A urine cup can come back clean and the person providing that sample can still have a potent synthetic opioid in their system. That is not a hypothetical. It is what is happening in forensic labs and treatment programs as nitazenes spread through the illicit drug supply. Nitazenes are a class of benzimidazole-opioids that were never approved for medical use anywhere in the world, and several analogs are now confirmed to exceed fentanyl in potency. The problem for anyone running a drug testing program is structural, not procedural. Standard opiate panels and fentanyl test strips are built to recognize specific chemical shapes, and nitazenes do not share that shape with either.
What nitazenes are
Nitazenes, chemically known as 2-benzylbenzimidazoles, were first synthesized in the 1950s during pharmaceutical research into opioid analgesics. They were never brought to market. Decades later they resurfaced in the illicit drug supply, first identified in adulterated heroin and counterfeit pills and increasingly found mixed into fentanyl, cocaine, and other street drugs. The DEA's Diversion Control Division confirms that nitazenes "can match or surpass the potency of fentanyl" and lists isotonitazene, metonitazene, and protonitazene among analogs under international and federal control, with additional benzimidazole-opioid substances placed under emergency Schedule I status in 2025.
Potency varies by analog. According to a CDC Morbidity and Mortality Weekly Report on nitazene-related deaths in Tennessee, "the potency of isotonitazene, protonitazene, and etonitazene greatly exceeds that of fentanyl, whereas the potency of metonitazene is similar to fentanyl." That same report documented a fourfold increase in nitazene-involved fatal overdoses in a single year, rising from 10 deaths to 42 as the drug supply shifted from isotonitazene to metonitazene as the dominant analog.
Why nitazenes do not trigger opiate (OPI/MOR) panels
Standard opiate immunoassay panels, the ones labeled OPI or MOR on a drug test cup, are built around antibodies that bind to the morphinan chemical structure shared by morphine, codeine, and their metabolites, including the heroin metabolite 6-acetylmorphine. Nitazenes are not morphinan compounds. They are benzimidazole-based molecules with a completely different core structure. An antibody trained to recognize the morphinan scaffold has nothing to grab onto in a nitazene molecule, so the test reads negative regardless of how much drug is present in the specimen.
This is the same reason semi-synthetic and fully synthetic opioids outside the morphinan family, like fentanyl itself, require their own dedicated immunoassay rather than relying on the opiate panel. Nitazenes take that gap one step further because they are not chemically related to fentanyl either.
Why fentanyl test strips are not a reliable backstop
Fentanyl test strips and fentanyl (FEN) immunoassay panels work the same way as opiate panels: an antibody keyed to the fentanyl molecule's specific structure. A laboratory evaluation of nitazene-specific test strips published in the National Library of Medicine's PubMed Central archive found that the manufacturer confirmed no cross-reactivity between nitazene test strips and fentanyl, methadone, or heroin, even at high concentrations. That finding cuts both ways. If a nitazene-specific strip does not react to fentanyl, a fentanyl-specific strip has no reason to react to a nitazene. The two compound classes simply do not share an antibody target.
Practically, this means a batch of drugs, or a person's system, can contain a nitazene and produce a negative fentanyl strip result and a negative opiate panel result at the same time. Neither test was designed to see it.
Comparison: what each test method actually detects
| Test method | What it targets | Detects nitazenes? | Notes |
|---|---|---|---|
| Standard OPI/MOR immunoassay panel | Morphinan-structure opioids (morphine, codeine, heroin metabolite) | No | Nitazenes are chemically unrelated to the morphinan scaffold |
| Fentanyl (FEN) immunoassay or test strip | Fentanyl-specific molecular structure | No, not reliably | Nitazenes do not cross-react with fentanyl antibodies |
| Nitazene-specific immunoassay test strip | Benzimidazole-opioid structure shared by many nitazene analogs | Partial | Detected roughly 24 of 33 analogs tested in lab evaluation; missed "desnitazenes" lacking the 5-nitro group |
| Confirmatory LC-MS/MS or GC-MS | Specific molecular mass and fragmentation pattern | Yes, when the analog is included in the testing method's scope | Requires a forensic or reference lab and a method built to look for nitazenes specifically |
What actually catches nitazenes
Confirmed nitazene detection currently depends on targeted laboratory methods, typically liquid chromatography tandem mass spectrometry or gas chromatography mass spectrometry, run at a forensic toxicology lab or reference lab that has specifically built the analyte into its testing panel. The CDC's Tennessee report is direct about why this matters for surveillance: "Traditional laboratory panels do not always capture nitazenes." In that dataset, the majority of nitazene-involved deaths were identified only because one county's forensic center routinely submitted samples to the DEA for secondary testing beyond the standard panel. Counties without that extra step likely had nitazene deaths that were never specifically identified as such.
Nitazene-specific immunoassay test strips, similar in format to fentanyl test strips, have started to appear as harm reduction tools. They are useful as a presumptive screen but not a substitute for lab confirmation. Researchers evaluating these strips in a study published through the National Institutes of Health's PubMed Central database cautioned that false negatives occurred for several analogs, meaning a negative strip result cannot rule out nitazene presence.
What treatment programs, medical examiners, and harm reduction workers should know
For treatment programs, a negative urine screen in a patient showing signs of opioid intoxication, sedation, or an overdose that required unusually high or repeated naloxone dosing is not proof that no opioid is on board. The CDC report on Tennessee deaths noted that naloxone reversed nitazene-involved overdoses, but multiple doses were often needed given the potency of several analogs, and only a minority of the people who died had received naloxone at all. Programs treating patients with opioid use disorder should treat a negative opiate and fentanyl panel alongside clear clinical signs of opioid effect as a reason to consider expanded or send-out testing, not as a reason to rule out synthetic opioid use.
Medical examiners and coroners doing postmortem toxicology in regions where nitazenes have been reported should not assume a standard panel is sufficient for cause-of-death determination in suspected opioid overdose cases. As the Tennessee data shows, without a deliberate decision to test beyond the routine panel, nitazene involvement can go entirely undocumented, which understates the true scope of the synthetic opioid supply in overdose statistics used for public health response.
Harm reduction workers distributing fentanyl test strips should communicate clearly that a negative fentanyl strip result does not mean a sample is free of other synthetic opioids. Nitazene-specific strips exist and can be distributed alongside fentanyl strips, but even those have documented gaps for certain analogs, particularly the desnitazene compounds that lack the chemical group most strips are built to detect.
Why a negative panel does not rule out synthetic opioid involvement
The core issue is that immunoassay drug testing, whether it is a 5-panel cup, a fentanyl strip, or a nitazene strip, works by antibody recognition of a specific molecular shape. Every time a new analog enters the illicit supply with a structure different enough from what existing antibodies were trained on, it can pass through those tests undetected. Nitazenes are a clear example: structurally distinct from morphinan opioids, structurally distinct from fentanyl, and only partially covered by the newest generation of nitazene-specific strips. That is why a negative result on any single immunoassay panel should be read as "this panel did not detect a substance it is built to detect," not as "no opioid is present."
Organizations that need broader coverage should look at expanded multi-panel testing that includes fentanyl and, where relevant to their population, consider building relationships with labs that run targeted nitazene confirmation. Reviewing panel configurations against what compounds are actually circulating regionally, and browsing American Screening Corp's full range of drug test panels, is a reasonable starting point for programs reassessing their testing scope.
Frequently asked questions
Do nitazenes show up on a standard drug test?
No. Standard opiate (OPI/MOR) immunoassay panels are built to detect morphinan-structure opioids like morphine, codeine, and heroin metabolites. Nitazenes are benzimidazole-opioids with a different chemical structure, so they do not trigger a positive result on a standard opiate panel.
Will a fentanyl test strip catch a nitazene?
Not reliably. Fentanyl test strips are built around antibodies specific to fentanyl's molecular structure. Laboratory research has found that nitazenes do not cross-react with fentanyl antibodies, meaning a fentanyl strip can read negative even when a nitazene is present in a sample or a person's system.
What test method actually detects nitazenes?
Confirmed detection requires either a nitazene-specific immunoassay test strip, which catches many but not all analogs, or targeted laboratory confirmation using liquid chromatography tandem mass spectrometry or gas chromatography mass spectrometry at a lab that has built nitazene analogs into its testing method.
Are nitazenes more dangerous than fentanyl?
Potency varies by analog. CDC data indicates isotonitazene, protonitazene, and etonitazene are more potent than fentanyl, while metonitazene is roughly similar in potency to fentanyl. Overdoses involving nitazenes have sometimes required multiple doses of naloxone to reverse.
Why do nitazene overdose deaths sometimes go undocumented?
Because routine toxicology panels used in many death investigations are not built to detect nitazenes. CDC reporting on nitazene deaths found that cases were identified largely where a forensic center took the extra step of sending samples for secondary testing beyond the standard panel, meaning many nitazene-involved deaths elsewhere may not be specifically identified as such.
For related reading, see Does Fentanyl Show Up on a Standard Drug Test? and Does a Standard Drug Test Detect Xylazine ("Tranq")? for how other emerging street drug additives interact with routine panels.
This article is general information, not medical or clinical advice. Testing program design, panel selection, and response to suspected synthetic opioid exposure should be guided by a qualified medical review officer, toxicologist, or clinical professional familiar with your program's needs and local drug supply trends.
